Market research
NURO NeuroMetrix Inc
NASDAQ USD Healthcare
Latest close
As of 30 May 2025
Test a moving-average rule with historical data.
Market facts
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 50
- Dividend yield
- Not available
- Beta
- 1.83
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 9M
- P/E ratio
- Not available
- Analyst target
- 50
- Dividend yield
- Not available
- Beta
- 1.83
About
About NeuroMetrix Inc
NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing and sale of medical devices. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; and Quell, a wearable device for symptomatic relief and management of chronic pain. The company offers its products to managed endocrinologists, podiatrists, primary care physicians, and other clinicians at the point-of care to objectively detect, stage, and monitor peripheral neuropathies. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Research context
NeuroMetrix Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the NURO discussion.
5 years, 7 months ago
NeuroMetrix, Inc is currently in a long term uptrend where the price is trading 14.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.4.
NeuroMetrix, Inc's total revenue rose by 6.0% to $2M since the same quarter in the previous year.
Its net income has increased by 100.2% to $2K since the same quarter in the previous year.
Finally, its free cash flow grew by 513.3% to $281K since the same quarter in the previous year.
Based on the above factors, NeuroMetrix, Inc gets an overall score of 5/5.